INVO Fertility Reports Third Quarter 2026 Results Highlighting 28% Clinic Revenue Growth and Continued Positive Clinic-Level Adjusted EBITDA

Record quarterly clinic revenues supported by both organic growth and acquisitions

Seventh consecutive quarter of positive Clinic-Level Adjusted EBITDA

Balance sheet continues to improve following debt repayments

SARASOTA, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility”, “INVO”, or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the third quarter ended September 30, 2026.

Q3 2026 Financial Highlights (all metrics compared to Q3 2025 unless otherwise noted)

  • Revenue increased 26% to $2,222,656 from $1,757,094.
  • Consolidated clinic revenue increased 28% to $2,207,587 from $1,722,223.
  • Net loss narrowed to $2.1 million from $3.4 million. Loss from operations improved to $1.5 million from $1.6 million.
  • Clinic-Level Adjusted EBITDA before corporate operating and public company expenses remained positive for the seventh consecutive quarter.
  • Consolidated Adjusted EBITDA was $(1.0) million, compared to $(0.9) million in Q3 2025.
  • Cash was $3.7 million at September 30, 2026, or approximately $3.10 per share.
  • As of November 13, 2026, the Company had 1,192,860 shares of common stock outstanding.
  • Further strengthening of the balance sheet compared to December 31, 2025 with assets increasing by $5.3 million, liabilities reduced by $5.5 million, and net equity of $18.0 million, or $15.09 per share.

Recent Highlights

  • Organic and acquired growth. Revenue grew at both the Wisconsin and Atlanta clinics as the practices continued their efforts to reach more patients. Management believes that Wisconsin’s entry into the Progyny network in the first quarter contributed to growth by expanding access for patients with Progyny coverage. The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each contributed a full quarter of revenue.
  • Clinic efficiency. INVO has implemented, and continues to evaluate, new tools to reduce time spent on documentation and administrative work across its practices, drawing on industry best practice. These initiatives are expected to continue driving improved patient experience and clinic-level efficiencies.
  • Positive industry feedback at ASRM. In October 2026, INVO attended the American Society for Reproductive Medicine Scientific Congress & Expo in Baltimore, resulting in further expansion of potential acquisition opportunities.
  • Improved balance sheet. INVO ended September with $3.7 million in cash and $4.5 million in current liabilities, down from $10.3 million in current liabilities at year-end 2025.
  • Planned investment in Birmingham. In June 2026, INVO acquired the remaining 50% interest in its Birmingham clinic for an agreed purchase price of $175,001 payable to the sellers. The purchase price reflected the investments INVO expected to make under full ownership, including recruiting a new physician and adding key services, and the temporary revenue disruption as the new physician ramps up.
  • Continued clinic-level profitability. The clinic network generated approximately $292,000 in Clinic-Level Adjusted EBITDA, its seventh consecutive positive quarter, after accounting for the approximate $193,000 impact in Q3 of the planned Birmingham acquisition transitioning.

Management Commentary

“Revenue grew again this quarter, and our clinics continued to generate positive Adjusted EBITDA before corporate expenses,” said Steve Shum, Chief Executive Officer of INVO Fertility. “We saw growth at our Wisconsin and Atlanta practices alongside the contribution from our acquisitions of the Indiana clinic and Birmingham clinic. That combination is what we set out to achieve by investing in our existing clinics and acquiring established practices.”

“We continue to see increased opportunities for acquisitions, which remain a key component to our growth objectives, as independent fertility practices look for ways to serve more patients while preserving the local relationships that patients and physicians value. As a publicly traded fertility clinic operator, INVO provides public market investors an alternative way to participate directly in that evolution and share in the potential growth of our clinic network. Equally important, we have purposely made key investments in people and additional infrastructure, in advance, in preparation to expand our network. We believe we have assembled an excellent team capable of executing on our growth plans and we look forward to leveraging our infrastructure as we expand and driving further operating performance.”

“Our balance sheet has also further strengthened in the period following the Wisconsin acquisition payment and the reduction in our current liabilities. We’re also focused on helping our clinics reach more patients and giving our clinical teams better tools and resources. Overall, the progress we’ve made and the opportunities we see on both sides of our growth strategy give us good reason to be excited about what comes next,” Shum concluded.

Third Quarter Financial Discussion

Revenue increased to approximately $2.2 million in the third quarter of 2026 from approximately $1.8 million in the prior-year quarter. Clinic revenue accounted for approximately $485,000 of year-over-year growth, reflecting higher revenue in Wisconsin and Atlanta and the addition of the Indiana and Birmingham clinics. Product revenue was approximately $15,000, compared to approximately $35,000 a year earlier. The decrease in product revenue partially reflects the elimination of sales to the Indiana and Birmingham clinics, which are now consolidated subsidiaries and treated as intercompany transactions.

Cost of services was approximately $1.4 million in the third quarter of 2026, primarily reflecting the cost of providing care across the expanded clinic network. Selling, general, and administrative expenses were approximately $2.1 million, compared to approximately $2.1 million a year earlier.

Loss from operations improved to approximately $1.5 million in the third quarter of 2026 from $1.6 million in the prior year. Net loss narrowed to approximately $2.1 million from approximately $3.4 million in the year-ago quarter.

Consolidated Adjusted EBITDA was $(1.0) million in the third quarter of 2026, compared with $(0.9) million in the prior-year quarter. This measure includes the cost of operating the public company and supporting the clinic network, including personnel in operations, human resources, and finance.

Clinic-Level Adjusted EBITDA was $292,114, compared with $243,120 in the prior-year quarter. The clinics generated positive Adjusted EBITDA before corporate expenses for the seventh consecutive quarter. The planned transition in Birmingham reduced the quarter’s clinic-level contribution by approximately $193,000 due to the anticipated revenue disruption and increased costs associated with bringing in a new physician.

At September 30, 2026, cash totaled approximately $3.7 million and current liabilities were approximately $4.5 million, compared to $2.1 million and $10.3 million, respectively, at December 31, 2025.

Clinic-Level Adjusted EBITDA

Clinic-Level Adjusted EBITDA was $292,114 in the third quarter of 2026, compared with $243,120 in the third quarter of 2025. The clinic network generated positive Adjusted EBITDA for the seventh consecutive quarter.

Management is focused on growing this contribution through higher patient volumes, expanded services, and improved operating execution, while also adding (via its acquisition efforts) established, profitable clinics that can increase scale and allow corporate operating expenses to be supported across a larger revenue and earnings base.

(Unaudited, in dollars, before corporate operating and public company expenses)

Fertility Clinic Services Segment Q3 2026 Q3 2025
Clinic revenue $2,207,587 $1,722,223
Operating expenses 2,144,678 1,592,534
Segment profit 62,909 129,689
Depreciation and amortization 36,273 113,431
Birmingham clinic – acquisition transition 192,932 –
Clinic-Level Adjusted EBITDA $292,114 $243,120

Clinic-Level Adjusted EBITDA is a non-GAAP measure. See Use of Non-GAAP Measures and the reconciliation below. Fertility Clinic Services Segment data derived from Note 15 – Segment Reporting in the Company’s third quarter 10-Q

Webcast

INVO Fertility will host a webcast to discuss its third quarter 2026 financial results and provide a business update.

Date and time: Monday, November 16, 2026, at 11:00 a.m. Eastern Time

Webcast registration: https://app.webinar.net/2WBLVyGJEq9

Replay: https://app.webinar.net/2WBLVyGJEq9

Use of Non-GAAP Measure

Included in this press release are references to Adjusted EBITDA and Clinic-Level Adjusted EBITDA, which are non-GAAP financial measures. These measures are not intended to be substitutes for financial measures reported in accordance with U.S. generally accepted accounting principles. Management believes that, when considered together with the GAAP figures, these measures provide meaningful information regarding operating performance, the earnings contribution of the Company’s clinic platform and trends in the business.

Clinic-Level Adjusted EBITDA represents Adjusted EBITDA generated by the Company’s fertility clinic operations before corporate operating expenses, as calculated by management. This measure is intended to provide visibility into the performance and earnings capacity of the operating clinic platform separately from the costs associated with managing a public company and building a larger acquisition platform. Adjusted EBITDA and Clinic-Level Adjusted EBITDA may be calculated differently by INVO Fertility than by other companies that disclose measures with the same or similar terms.

About INVO Fertility

We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics and related businesses and technologies. Our acquisition strategy focuses on US-based, profitable fertility clinics. Our clinics offer a variety of fertility services including in vitro fertilization (“IVF”) and the intravaginal culture (“IVC”) procedure enabled by INVOcell. We have four operational fertility clinics in the United States. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman’s body. For more information, please visit invofertility.com.

Safe Harbor Statement

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements regarding organic growth initiatives, acquisition opportunities, integration of acquired clinics, balance sheet improvements, liquidity, the growth of our clinic platform and our ability to achieve cash flow break even or profitability, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.

For more information, please contact:

INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invofertility.com

Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com

INVO FERTILITY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
 
    For the Three Months
Ended September 30,
    For the Nine Months
Ended September 30,
 
    2026     2025     2026     2025  
                         
Revenue:                                
Clinic revenue   $ 2,207,587     $ 1,722,223     $ 6,357,605     $ 5,175,870  
Product revenue     15,069       34,871       55,761       82,063  
Total revenue     2,222,656       1,757,094       6,413,366       5,257,933  
Operating expenses:                                
Cost of services     1,436,870       1,121,174       4,071,782       3,252,659  
Cost of goods sold     14,144       6,575       79,443       13,622  
Selling, general, and administrative expenses     2,071,438       2,128,088       6,154,287       5,878,459  
Impairment loss     –       –       –       1,397,353  
Depreciation and amortization     177,564       136,741       465,835       540,940  
Total operating expenses     3,700,016       3,392,578       10,771,347       11,083,033  
Loss from operations     (1,477,360 )     (1,635,484 )     (4,357,981 )     (5,825,100 )
Other income (expense):                                
Gain from equity method joint ventures     –       12,827       15,014       8,012  
Gain on remeasurement     –       –       2,452,032       –  
Gain (loss) on change in fair value of derivatives     (562,997 )     (33,566 )     (4,353,222 )     1,626,594  
Loss on debt extinguishment     –       (1,416,610 )     (172,621 )     (2,108,880 )
Gain on settlement     –       –       –       939,500  
Interest income     74,735       –       214,249       –  
Interest expense     (154,768 )     (322,765 )     (512,318 )     (1,071,200 )
Total other income (expense)     (643,030 )     (1,760,114 )     (2,356,866 )     (605,974 )
Net loss from continuing operations before income taxes     (2,120,390 )     (3,395,598 )     (6,714,847 )     (6,431,074 )
Provision for income taxes     29,530       –       85,684       –  
Net loss from continuing operations     (2,149,920 )     (3,395,598 )     (6,800,531 )     (6,431,074 )
Discontinued operations (Note 5)                                
Loss on disposal of NTI     –       –       –       (1,534,517 )
Loss on discontinued operations of NTI     –       –       –       (16,452,562 )
Net loss   $ (2,149,920 )   $ (3,395,598 )   $ (6,800,531 )   $ (24,418,153 )
                                 
Net Loss from continuing operations per share                                
Basic   $ (2.44 )   $ (157.43 )   $ (11.20 )   $ (722.84 )
Diluted   $ (2.44 )   $ (157.43 )   $ (11.20 )   $ (722.84 )
Loss from discontinued operations per common share                                
Basic   $ –     $ –     $ –     $ (2,021.70 )
Diluted   $ –     $ –     $ –     $ (2,021.70 )
Net Loss per common share:                                
Basic   $ (2.44 )   $ (157.43 )   $ (11.20 )   $ (2,744.54 )
Diluted   $ (2.44 )   $ (157.43 )   $ (11.20 )   $ (2,744.54 )
Weighted average number of common shares outstanding:                                
Basic     880,233       21,569       607,101       8,897  
Diluted     880,233       21,569       607,101       8,897  

INVO FERTILITY, INC.
CONSOLIDATED BALANCE SHEETS


 
    September 30,
2026
    December 31,
2025
 
    (Unaudited)        
ASSETS                
Current assets                
Cash   $ 3,695,770     $ 2,077,842  
Accounts receivable, net of allowances of $140,089 and $69,641 as of September 30, 2026 and December 31, 2025, respectively     170,423       217,263  
Inventory, net of allowances of $0 as of September 30, 2026 and December 31, 2025     230,806       225,253  
Prepaid expenses and other current assets     347,840       241,145  
Total current assets     4,444,839       2,761,503  
Property and equipment, net     814,175       386,165  
Lease right of use     2,052,056       1,286,217  
Intangible assets, net     1,245,345       1,325,145  
Goodwill     9,236,642       5,878,986  
Investment in NAYA Therapeutics     2,466,810       2,466,810  
Note receivable – NAYA Therapeutics     5,240,333       5,029,770  
Note receivable – HRCFG     –       1,085,528  
                 
Total assets   $ 25,500,200     $ 20,220,124  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
Current liabilities                
Accounts payable and accrued liabilities   $ 1,297,870     $ 2,034,057  
Accrued compensation     377,110       285,946  
Notes payable – current portion, net     577,108       394,664  
Convertible note payable – related party, net     17,882       880,000  
Deferred revenue     728,630       721,897  
Lease liability, current portion     413,117       208,987  
Additional payments for acquisitions, current portion     998,000       3,925,000  
Warrant liability     –       1,881,078  
Other current liabilities     47,812       –  
Total current liabilities     4,457,529       10,331,629  
Lease liability, net of current portion     1,769,838       1,171,075  
Liability for excess losses of equity method investee     –       448,474  
Notes payable – net of current portion     362,445       744,725  
Derivative liability     745,288       –  
Deferred tax liability     80,159       –  
Other liabilities, net of current portion     79,688       –  
Additional payments for acquisition, net of current portion     –       300,000  
Total liabilities   $ 7,494,947     $ 12,995,903  
                 
Stockholders’ equity                
Series C-2 Preferred Stock, $1,000.00 par value; 20,000 shares authorized; 0 and 3,004 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively   $ –     $ 2,406,359  
Series D Preferred Stock, $1,000.00 par value, 400 shares authorized; 400 and 0 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     400,000       –  
Common Stock, $.0001 par value; 62,500,000 shares authorized; 1,192,860 and 119,358 issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     119       11  
Additional paid-in capital     115,790,672       96,187,254  
Accumulated deficit     (98,185,538 )     (91,369,403 )
Total stockholders’ equity     18,005,253       7,224,221  
Total liabilities and stockholders’ equity   $ 25,500,200     $ 20,220,124  

Adjusted EBITDA        
    For the Three Months Ended
    September 30,
      2026       2025  
Net loss from continuing operations   $ (2,149,920 )   $ (3,395,598 )
Interest expense     154,768       322,765  
Interest income     74,735       –  
Tax expense     29,530       –  
Depreciation and amortization     177,564       136,741  
Stock-based compensation     188,622       493,348  
Non cash compensation for services     –       45,000  
Gain on remeasurement     –       –  
Gain on change in fair value of warrant liability     562,997       33,566  
Loss from debt extinguishment     –       1,416,610  
Adjusted EBITDA   $ (961,704 )   $ (947,568 )


Primary Logo

Media gallery